Partner Fund Management
Latest statistics and disclosures from PFM Health Sciences's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, THC, CYTK, ABBV, VRTX, and represent 34.24% of PFM Health Sciences's stock portfolio.
- Added to shares of these 10 stocks: INSP (+$21M), ACHC (+$17M), ASND (+$14M), WAT (+$11M), Concentra Group Holdings Par (+$6.7M), Ascendis Pharma A/s (+$5.8M), TGTX (+$5.5M), VEEV, KROS, LBPH.
- Started 11 new stock positions in OCUL, CAPR, VERV, VEEV, LBPH, ARKG, Concentra Group Holdings Par, TGTX, INSP, ASND. LUNG.
- Reduced shares in these 10 stocks: QQQ (-$90M), , UNH (-$27M), DXCM (-$26M), XBI (-$25M), EW (-$23M), ACLX (-$21M), BSX (-$20M), JNJ (-$19M), SYK (-$17M).
- Sold out of its positions in APLS, Biomarin Pharma Inc convertible/, CNC, DXCM, EYPT, QQQ, IWM, JNJ, MDGL, OM. SANA, TNYA, VKTX, WAY.
- PFM Health Sciences was a net seller of stock by $-332M.
- PFM Health Sciences has $1.8B in assets under management (AUM), dropping by -12.67%.
- Central Index Key (CIK): 0001442756
Tip: Access up to 7 years of quarterly data
Positions held by Partner Fund Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for PFM Health Sciences
PFM Health Sciences holds 74 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 15.0 | $265M | 299k | 885.94 |
|
|
| Tenet Healthcare Corp Com New (THC) | 5.6 | $98M | 589k | 166.20 |
|
|
| Cytokinetics Com New (CYTK) | 5.3 | $93M | 1.8M | 52.80 |
|
|
| Abbvie (ABBV) | 4.5 | $80M | 404k | 197.48 |
|
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.9 | $69M | 149k | 465.08 |
|
|
| Intuitive Surgical Com New (ISRG) | 3.8 | $68M | 137k | 491.27 |
|
|
| Merck & Co (MRK) | 3.5 | $62M | -8% | 543k | 113.56 |
|
| Hca Holdings (HCA) | 2.9 | $51M | 125k | 406.43 |
|
|
| Universal Hlth Svcs CL B (UHS) | 2.8 | $49M | 214k | 229.01 |
|
|
| McKesson Corporation (MCK) | 2.7 | $48M | 98k | 494.42 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 2.7 | $47M | 87k | 542.08 |
|
|
| UnitedHealth (UNH) | 2.5 | $44M | -37% | 76k | 584.68 |
|
| Acadia Healthcare (ACHC) | 2.5 | $44M | +63% | 686k | 63.41 |
|
| Axsome Therapeutics (AXSM) | 2.4 | $42M | 467k | 89.87 |
|
|
| Thermo Fisher Scientific (TMO) | 2.0 | $36M | -8% | 58k | 618.57 |
|
| Danaher Corporation (DHR) | 2.0 | $35M | 126k | 278.02 |
|
|
| Spdr Ser Tr S&p Biotech Call Option (XBI) | 1.9 | $34M | -42% | 340k | 98.80 |
|
| Icon SHS (ICLR) | 1.9 | $34M | 117k | 287.31 |
|
|
| Penumbra (PEN) | 1.8 | $32M | -10% | 166k | 194.31 |
|
| Humana (HUM) | 1.8 | $32M | -18% | 102k | 316.74 |
|
| Anthem (ELV) | 1.7 | $29M | +2% | 56k | 520.00 |
|
| Amgen (AMGN) | 1.6 | $29M | +11% | 90k | 322.21 |
|
| Ascendis Pharma A/s Note 2.250% 4/0 (Principal) | 1.5 | $27M | +27% | 23M | 1.17 |
|
| Iqvia Holdings (IQV) | 1.5 | $27M | 112k | 236.97 |
|
|
| Edwards Lifesciences (EW) | 1.5 | $26M | -47% | 391k | 65.99 |
|
| Becton, Dickinson and (BDX) | 1.4 | $25M | -22% | 102k | 241.10 |
|
| Stryker Corporation (SYK) | 1.4 | $24M | -41% | 67k | 361.26 |
|
| Molina Healthcare (MOH) | 1.4 | $24M | 70k | 344.56 |
|
|
| Inspire Med Sys (INSP) | 1.2 | $21M | NEW | 98k | 211.05 |
|
| Waters Corporation (WAT) | 1.0 | $18M | +148% | 51k | 359.89 |
|
| Oscar Health Cl A (OSCR) | 1.0 | $18M | 861k | 21.21 |
|
|
| Essa Pharma Com New (EPIX) | 0.9 | $17M | -7% | 2.7M | 6.06 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.8 | $14M | NEW | 91k | 149.31 |
|
| Erasca (ERAS) | 0.8 | $13M | +4% | 4.9M | 2.73 |
|
| Insmed Com Par $.01 (INSM) | 0.6 | $11M | -36% | 152k | 73.00 |
|
| Sarepta Therapeutics (SRPT) | 0.6 | $11M | 88k | 124.89 |
|
|
| Celcuity (CELC) | 0.6 | $11M | -15% | 710k | 14.91 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.6 | $11M | -59% | 183k | 57.54 |
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.5 | $9.5M | -4% | 10M | 0.95 |
|
| Boston Scientific Corporation (BSX) | 0.5 | $9.1M | -68% | 109k | 83.80 |
|
| Sarepta Therapeutics Note 1.250% 9/1 (Principal) | 0.5 | $8.8M | 7.8M | 1.14 |
|
|
| Caribou Biosciences (CRBU) | 0.5 | $8.4M | +5% | 4.3M | 1.96 |
|
| Syndax Pharmaceuticals (SNDX) | 0.5 | $8.2M | +9% | 424k | 19.25 |
|
| Werewolf Therapeutics (HOWL) | 0.4 | $7.2M | +4% | 3.4M | 2.12 |
|
| Xenon Pharmaceuticals (XENE) | 0.4 | $7.1M | +19% | 180k | 39.37 |
|
| Concentra Group Holdings Par Common Stock | 0.4 | $6.7M | NEW | 300k | 22.36 |
|
| Keros Therapeutics (KROS) | 0.3 | $5.9M | +202% | 101k | 58.07 |
|
| Alkermes SHS (ALKS) | 0.3 | $5.7M | 205k | 27.99 |
|
|
| Intra Cellular Therapies (ITCI) | 0.3 | $5.7M | -54% | 77k | 73.17 |
|
| Tg Therapeutics (TGTX) | 0.3 | $5.5M | NEW | 233k | 23.39 |
|
| Arcellx Common Stock (ACLX) | 0.3 | $5.1M | -80% | 61k | 83.51 |
|
| Day One Biopharmaceuticals I (DAWN) | 0.3 | $4.8M | -13% | 342k | 13.93 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.2 | $4.3M | -57% | 269k | 15.99 |
|
| Veeva Sys Cl A Com (VEEV) | 0.2 | $4.0M | NEW | 19k | 209.87 |
|
| Longboard Pharmaceuticals In (LBPH) | 0.2 | $3.8M | NEW | 114k | 33.33 |
|
| Ocular Therapeutix (OCUL) | 0.2 | $3.5M | NEW | 403k | 8.70 |
|
| Immunovant (IMVT) | 0.2 | $3.5M | -74% | 123k | 28.51 |
|
| Cullinan Oncology (CGEM) | 0.2 | $3.1M | -38% | 183k | 16.74 |
|
| Pulmonx Corp (LUNG) | 0.2 | $3.1M | NEW | 369k | 8.29 |
|
| Pmv Pharmaceuticals (PMVP) | 0.2 | $3.0M | +57% | 2.0M | 1.49 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.2 | $2.8M | -58% | 451k | 6.30 |
|
| Io Biotech (IOBT) | 0.1 | $2.5M | 2.3M | 1.05 |
|
|
| Capricor Therapeutics Com New (CAPR) | 0.1 | $2.3M | NEW | 153k | 15.21 |
|
| Metagenomi (MGX) | 0.1 | $2.2M | -18% | 1.0M | 2.17 |
|
| Ark Etf Tr Genomic Rev Etf (ARKG) | 0.1 | $2.2M | NEW | 87k | 25.60 |
|
| Inhibrx Biosciences (INBX) | 0.1 | $2.1M | 136k | 15.66 |
|
|
| Generation Bio (GBIO) | 0.1 | $1.9M | 788k | 2.47 |
|
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $1.8M | 649k | 2.77 |
|
|
| Celldex Therapeutics Com New (CLDX) | 0.1 | $1.8M | 52k | 33.99 |
|
|
| Iovance Biotherapeutics (IOVA) | 0.1 | $1.2M | -13% | 132k | 9.39 |
|
| Boundless Bio (BOLD) | 0.0 | $835k | +71% | 241k | 3.47 |
|
| Verve Therapeutics (VERV) | 0.0 | $610k | NEW | 126k | 4.84 |
|
| Uniqure Nv SHS (QURE) | 0.0 | $600k | -55% | 122k | 4.93 |
|
| Turnstone Biologics Corp (TSBX) | 0.0 | $519k | 932k | 0.56 |
|
Past Filings by PFM Health Sciences
SEC 13F filings are viewable for PFM Health Sciences going back to 2010
- PFM Health Sciences 2024 Q3 filed Nov. 14, 2024
- PFM Health Sciences 2024 Q2 filed Aug. 14, 2024
- PFM Health Sciences 2024 Q1 filed May 14, 2024
- PFM Health Sciences 2023 Q4 filed Feb. 14, 2024
- PFM Health Sciences 2023 Q3 filed Nov. 14, 2023
- PFM Health Sciences 2023 Q2 filed Aug. 14, 2023
- PFM Health Sciences 2023 Q1 filed May 15, 2023
- PFM Health Sciences 2022 Q4 filed Feb. 14, 2023
- PFM Health Sciences 2022 Q3 filed Nov. 14, 2022
- PFM Health Sciences 2022 Q2 filed Aug. 15, 2022
- PFM Health Sciences 2022 Q1 filed May 16, 2022
- PFM Health Sciences 2021 Q4 filed Feb. 14, 2022
- PFM Health Sciences 2021 Q3 filed Nov. 15, 2021
- PFM Health Sciences 2021 Q2 filed Aug. 16, 2021
- PFM Health Sciences 2021 Q1 filed May 17, 2021
- PFM Health Sciences 2020 Q4 restated filed Feb. 19, 2021